Piramal Pharma Limited (PPL), a part of the Piramal Group, operates across three key segments:
Contract Development and Manufacturing Organization (CDMO),
Complex Hospital Generics (Critical Care), and
Consumer Healthcare (Over-the-Counter or OTC) products.
The company entered the pharmaceutical space in 1988 through the acquisition of Nicholas Laboratories and has since expanded through a series of strategic mergers, acquisitions, and organic growth initiatives. In 2010, Piramal sold its domestic formulations business to Abbott for $3.7 billion, and its diagnostic services business to Super Religare Laboratories (SRL).
